Company research
Acrivon Therapeutics, Inc.
CIK 1781174Updated Sep 27, 2026
SecurityACRV · NASDAQ · equity
ACRV price & chart
Loading TradingView…
NASDAQ:ACRV on TradingView ↗In the news
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 129,717,000Source | 196,588,000Source | 138,265,000Source | 181,226,000Source |
| Property, Plant and Equipment, NetUSD | 4,889,000Source | 4,471,000Source | 3,479,000Source | 2,092,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 41,499,000Source | 39,818,000Source | 36,015,000Source | 29,519,000Source |
| Assets, CurrentUSD | 120,445,000Source | 181,629,000Source | 129,692,000Source | 132,095,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,863,000Source | 2,149,000Source | 2,234,000Source | 4,344,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,527,000Source | 3,554,000Source | 4,429,000Source | 4,770,000Source |
| Other Assets, NoncurrentUSD | 1,653,000Source | 1,647,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 17,201,000Source | 19,802,000Source | 17,070,000Source | 10,751,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 31,000Source | 31,000Source | 23,000Source | 22,000Source |
| Additional Paid in CapitalUSD | 387,255,000Source | 373,284,000Source | 237,675,000Source | 226,580,000Source |
| Retained Earnings (Accumulated Deficit)USD | -274,881,000Source | -196,976,000Source | -116,420,000Source | -56,032,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 111,000Source | 447,000Source | -83,000Source | -95,000Source |
| Stockholders' Equity Attributable to ParentUSD | 112,516,000Source | 176,786,000Source | 121,195,000Source | 170,475,000Source |
| Liabilities and EquityUSD | 129,717,000Source | 196,588,000Source | 138,265,000Source | 181,226,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 15,664,000Source | 17,214,000Source | 13,303,000Source | 6,516,000Source |
| Operating Lease, Liability, CurrentUSD | 1,172,000Source | 1,057,000Source | 877,000Source | 726,000Source |
| Accounts Payable, CurrentUSD | 2,277,000Source | 758,000Source | 5,048,000Source | 904,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,537,000Source | 2,588,000Source | 3,767,000Source | 4,235,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 1,099,000Source | 1,272,000Source | 1,527,000Source | 1,785,000Source |
| Short-term InvestmentsUSD | 77,083,000Source | 139,662,000Source | 91,443,000Source | 98,232,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -77,905,000Source | -80,556,000Source | -60,388,000Source | -31,167,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,720,000Source | 14,288,000Source | 11,618,000Source | 2,185,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,536,000Source | -3,586,000Source | 3,609,000Source | -245,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -63,665,000Source | -65,669,000Source | -42,641,000Source | -30,117,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 66,100,000Source | -51,771,000Source | 50,717,000Source | -141,676,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,669,000Source | 2,768,000Source | 1,288,000Source | 2,166,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 750,000Source | 2,520,000Source | 1,297,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -749,000Source | 121,027,000Source | -1,554,000Source | 101,709,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,686,000Source | 3,587,000Source | 6,522,000Source | -70,084,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 41,702,000Source | 40,016,000Source | 36,429,000Source | 29,907,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 14,720,000Source | 14,288,000Source | 11,618,000Source | 2,185,000Source |
| DepreciationUSD | 1,356,000Source | 1,006,000Source | 536,000Source | 364,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 200,000Source | -100,000Source | 100,000Source | — |
| General and Administrative ExpenseUSD | 24,124,000Source | 25,207,000Source | 21,079,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | 7,000,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -77,905,000Source | -80,556,000Source | -60,388,000Source | -31,167,000Source |
| Nonoperating Income (Expense)USD | 6,209,000Source | 8,643,000Source | — | 1,490,000Source |
| Operating ExpensesUSD | 84,114,000Source | 89,199,000Source | 67,103,000Source | 32,657,000Source |
| Other Nonoperating Income (Expense)USD | -270,000Source | -558,000Source | 6,715,000Source | 1,490,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,000Source | 90,000Source | 775,000Source | 24,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | -100,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -84,114,000Source | -89,199,000Source | -67,103,000Source | -32,657,000Source |
| Other Nonoperating Income (Expense)USD | -270,000Source | -558,000Source | 6,715,000Source | 1,490,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -77,825,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -77,905,000Source | -80,556,000Source | -60,388,000Source | -31,167,000Source |
| Earnings Per Share, BasicUSD per share | -2.02Source | -2.38Source | -2.74Source | -7.56Source |
| Earnings Per Share, DilutedUSD per share | -2.02Source | -2.38Source | -2.74Source | -7.56Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 38,509,281Source | 33,791,817Source | 22,078,190Source | 4,121,912Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 38,509,281Source | 33,791,817Source | 22,078,190Source | 4,121,912Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 200,000Source | -100,000Source | 100,000Source | — |
| General and Administrative ExpenseUSD | 24,124,000Source | 25,207,000Source | 21,079,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -78,014,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | 6,479,000Source | 9,201,000Source | — | — |
| Investment Income, InterestUSD | — | — | 7,000,000Source | — |
| Nonoperating Income (Expense)USD | 6,209,000Source | 8,643,000Source | — | 1,490,000Source |
| Operating ExpensesUSD | 84,114,000Source | 89,199,000Source | 67,103,000Source | 32,657,000Source |
| Research and Development ExpenseUSD | 59,990,000Source | 63,992,000Source | 46,024,000Source | — |
Filing attachments
acrv-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 acrv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion phase supported by a promising, favorable safety profile and durable single-agent cli…
Read attachment ↗acrv-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 acrv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 The ACR-2316 Phase 1/2 study is advancing towards expansion phase demonstrating favorable tolerability, p…
Read attachment ↗acrv-ex99_1.htm · 8-K · 2026-03-19
EX-99.1 2 acrv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need subtype responsible for ~50…
Read attachment ↗acrv-ex99_2.htm · 8-K · 2026-03-19
EX-99.2 3 acrv-ex99_2.htm EX-99.2 ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) NEXT GENERATION PRECISION MEDICINE CORPORATE PRESENTATION MARCH 2026 Exhibit 99.2 Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operation…
Read attachment ↗